MEI Pharma, Inc. (MEIP)
NASDAQ: MEIP · Real-Time Price · USD
2.500
+0.040 (1.63%)
Dec 20, 2024, 4:00 PM EST - Market closed
MEI Pharma Revenue
In the fiscal year ending June 30, 2024, MEI Pharma had annual revenue of $65.30M with 33.76% growth.
Revenue (ttm)
$65.30M
Revenue Growth
+33.76%
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
28
Market Cap
16.66M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Jun 30, 2024 | 65.30M | 16.48M | 33.76% |
Jun 30, 2023 | 48.82M | 8.12M | 19.95% |
Jun 30, 2022 | 40.70M | 5.90M | 16.96% |
Jun 30, 2021 | 34.80M | 7.04M | 25.36% |
Jun 30, 2020 | 27.76M | 22.84M | 464.72% |
Jun 30, 2019 | Pro | Pro | Pro |
Jun 30, 2018 | Pro | Pro | Pro |
Jun 30, 2017 | Pro | Pro | Pro |
Jun 30, 2016 | Pro | Pro | Pro |
Jun 30, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionMEIP News
- 5 weeks ago - MEI Pharma Reports First Quarter Fiscal Year 2025 Cash Position - Business Wire
- 3 months ago - MEI Pharma Reports Fiscal Year End 2024 Cash Position - Business Wire
- 4 months ago - MEI Pharma Engages Oppenheimer & Co. Inc. to Assist in Evaluating Strategic Alternatives - Business Wire
- 5 months ago - MEI Pharma to Consider Strategic Alternatives - Business Wire
- 7 months ago - Glancy Prongay & Murray LLP Announces Investigation of MEI Pharma, Inc. (MEIP) - Business Wire
- 8 months ago - MEI Pharma Reports Third Quarter Fiscal Year 2024 Results and Operational Highlights - Business Wire
- 9 months ago - MEI Pharma Board of Directors Aligns on Strategy to Advance Voruciclib and ME-344 - Business Wire
- 9 months ago - MEI Pharma Reports Initial Data from Clinical Study Evaluating ME-344 in Combination with Bevacizumab (Avastin®) in Relapsed Metastatic Colorectal Cancer Patients - Business Wire